The familial hypercholesterolemia treatment market is projected to grow from USD 2,321.9 million in 2026 to USD 4,525.0 million by 2036, at a CAGR of 6.9%. Genetic sequencing tests will dominate with a 34.0% market share, while initial diagnosis will lead the applications segment with a 42.0% share.